ADPT vs NEO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ADPT and NEO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ADPT and NEO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Adaptive Biotechnologies (NASDAQ: ADPT) runs an immune-medicine platform built around reading the genetics of the adaptive immune system. Its commercial engine is clonoSEQ, an FDA-cleared minimal residual disease (MRD) test that measures how many cancer cells remain in a patient during and after treatment, used mainly in blood cancers such as multiple myeloma, ALL, and CLL. The MRD segment now contributes roughly 95 percent of revenue and includes both clinical testing and pharma partnerships that use the platform in drug trials. A second Immune Medicine arm pursues drug discovery and includes a long-running collaboration with Genentech on neoantigen-directed T-cell therapies.

Full ADPT guide

NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026.

Full NEO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ADPT drivers: clonoSEQ MRD volume and reimbursement; Pharma and biopharma partnerships.
• NEO drivers: Mix shift into NGS carries the revenue line; Margin discipline turning into real adjusted EBITDA.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: ADPT still runs at a net loss on a consolidated basis, so continued cash burn from the Immune Medicine arm and the cost of scaling clonoSEQ are ongoing concerns. For NEO, gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ADPT if you believe its drivers more; NEO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ADPT and NEO guides.

ADPT. As of July 2026 ADPT trades at a high revenue multiple typical of a growing, near-breakeven diagnostics company rather than on earnings, since it remains unprofitable on a consolidated basis. The large cash balance relative to burn gives multi-year runway. Valuation hinges heavily on continued MRD volume growth and how the market treats a potential separation.

NEO. With no trailing earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.7 times trailing revenue and roughly 40 times the midpoint of guided 2026 adjusted EBITDA. That second figure only looks reasonable if margin expansion continues for several more years, which is the crux of the debate on the name. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from $5.94 to $16.92 over the past 52 weeks.

Headline figures (approximate, July 2026): ADPT shows revenue (ttm) ~$250M, q1 2026 revenue ~$70.9M (up ~35% YoY), 2026 mrd revenue guidance ~$260M to $270M, q1 2026 net loss ~$20M (improved from ~$30M); NEO shows revenue (ttm) ~$766M (four quarters ended June 30, 2026), q2 2026 revenue ~$202M, up ~11% year over year, market cap ~$2.1B (~$16 per share on ~128.5M shares), price to sales ~2.7x trailing; enterprise value ~$2.3B, or ~3.0x sales.

ADPT and NEO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ADPT and NEO exposure against your real portfolio. It is not an investment adviser.